GTX Inc. About
GTX GTx is a biopharmaceutical company dedicated to the
discovery, development and commercialization GTX's drug discovery and development
programs are focused on small molecules that selectively modulate the effects
of estrogens and androgens,
two essential classes of hormones. GTx’s marketed compound is FARESTON®
(toremifene citrate 60mg) tablets for the treatment of metastatic breast
cancer. In two of the clinical programs, the company is developing
the same active compound, toremifene citrate, as ACAPODENE™ for two separate
indications in men: (1) for the prevention of prostate
cancer in high risk men and (2) a clinical trial for the treatment of serious
side effects of androgen deprivation therapy for advanced prostate cancer.
In its third clinical program, GTx and its partner, Ortho Biotech Products, L.P.,
a subsidiary of Johnson & Johnson, are developing andarine, a selective
androgen receptor modulator (SARM) In its fourth clinical program,
GTx is developing its second SARM, ostarine, for andropause and
other conditions related to aging, including sarcopenia. In addition, GTx
has an extensive preclinical pipeline (see below) More
on GTX Key
Statistics for GTX
Basic
Chart for GTX